Amanda Williams Buys 5,857 Shares of Aclarion (NASDAQ:ACON) Stock

Aclarion, Inc. (NASDAQ:ACON) Director Amanda Williams purchased 5,857 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were bought at an average cost of $2.73 per share, with a total value of $15,989.61. Following the transaction, the director directly owned 25,857 shares of the company’s stock, valued at approximately $70,589.61. This represents a 29.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Aclarion Trading Down 2.9%

Shares of NASDAQ:ACON opened at $2.69 on Friday. The firm has a market cap of $7.75 million, a PE ratio of -0.36 and a beta of 1.21. The company has a fifty day simple moving average of $2.67 and a 200 day simple moving average of $2.97. Aclarion, Inc. has a 12-month low of $1.95 and a 12-month high of $12.03.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Aclarion had a negative net margin of 10,948.81% and a negative return on equity of 59.34%. As a group, equities research analysts forecast that Aclarion, Inc. will post -4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ACON shares. Weiss Ratings raised Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Ascendiant Capital Markets increased their price target on Aclarion from $7.00 to $7.50 and gave the stock a “buy” rating in a research report on Friday, May 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.